IOVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Iovance Biotherapeutics Inc (IOVA) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. While there are positive developments in revenue growth and analyst upgrades, the company's financials remain weak with negative net income and EPS. Additionally, technical indicators do not show a clear bullish trend, and the stock lacks strong proprietary trading signals. It is better to wait for stronger signs of financial and operational stability before investing.
The MACD histogram is negative (-0.132) but contracting, RSI is neutral at 38.396, and moving averages are converging. The stock is trading below the pivot level of 3.81, with key support at 3.512 and resistance at 4.108. Overall, the technical indicators do not suggest a strong bullish trend.
Hedge funds are significantly increasing their positions (+296.59% last quarter). Analysts have raised price targets, with some highlighting operational improvements and potential undervaluation. The regenerative medicine market, including cell therapy, is projected to grow significantly, which could benefit Iovance in the long term.
The company reported a net income loss of -$71.9M in Q4 2025, with EPS dropping by -30.77% YoY. Insider trading activity is neutral, and there is no recent congress trading data. Technical indicators do not show a clear upward trend, and the stock has a 60% chance of declining by -15.06% in the next month based on historical patterns.
In Q4 2025, revenue increased by 17.74% YoY to $86.77M, and gross margin improved to 39.35%. However, net income dropped by -8.47% YoY to -$71.9M, and EPS declined by -30.77% YoY to -0.18. The company is still operating at a loss, which raises concerns about its financial health.
Analysts have mixed ratings. UBS, Baird, and Goldman Sachs maintain neutral or sell ratings with price targets between $2-$4. Citizens and Barclays are more optimistic, with price targets of $5 and $11, citing operational improvements and undervaluation. Chardan remains bullish with a $16 target but highlights ongoing pipeline risks.
